The anti‐C5a antibody vilobelimab efficiently inhibits C5a in patients with severe COVID‐19

Por Alexander P. J. Vlaar, Endry H. T. Lim, Sanne deBruin, Simon Rückinger, Korinna Pilz, Matthijs C. Brouwer, Ren‐Feng Guo, Leo M. A. Heunks, Matthias H. Busch, Pieter vanPaassen, Niels C. Riedemann, Diederik van deBeek
Publicado em 2022-04-01